Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Anakinra (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACTION
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 Nov 2017.
- 06 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.